Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan Life Science Investing
Emyria’s Specialist Psychiatrist Granted Authorised Prescriber Status in MDMA-Assisted Therapy for PTSD Life Science Investing
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement Psychedelics Investing
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024 Psychedelics Investing
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder Psychedelics Investing
Goodness Growth Holdings Announces Departure of General Counsel & Chief Compliance Officer Psychedelics Investing
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry Psychedelics Investing
